Whole Child Care

The Reframe

A Diagnosis Is Not One Condition. It Is Many.

The prevailing model treats a neurodevelopmental diagnosis as a single condition addressed by a single dominant therapy. The clinical reality is different. Autism and related neurodevelopmental conditions are better understood as an intermingled set of comorbidities that a child develops and carries over time — medical, behavioral, and developmental problems that compound one another. Roughly 40% of children with autism have co-occurring intellectual disability, with another quarter in the borderline range. Nearly half experience gastrointestinal symptoms. Between 50% and 80% have disrupted sleep. About one in ten develops epilepsy. Roughly 28% meet criteria for ADHD and 20% for an anxiety disorder, and feeding difficulties and motor-coordination problems are common. These are not footnotes to a diagnosis. Lived day to day, they are the diagnosis.

And they are routinely missed. Sleep disturbance is present in a majority of children with autism but formally diagnosed in a minority. The pain of untreated reflux or constipation, or the disorientation of an unrecognized seizure, is frequently recorded as “behavior” — a failure clinicians call diagnostic overshadowing. When the underlying medical driver is invisible, the system responds to the surface behavior and never reaches the cause. A child does not outgrow an untreated comorbidity. They accumulate the consequences of it.

CDC MMWR / ADDM Network (2025) · Wang et al., Front. Psychiatry (2022) · Liu et al., Autism (2022) · Lai et al., Lancet Psychiatry (2019)

The Cost of Fragmentation

Untreated Comorbidity Does Not Disappear. It Compounds.

When the whole child is not treated, the unaddressed problems do not resolve. They escalate into the most expensive settings in the system. Consider the default response to difficult behavior: medication. Among young children with autism who are prescribed a psychotropic, roughly 60% never received behavioral therapy at all. Nearly half of Medicaid-enrolled youth with autism are on at least one psychotropic in a given year, and about one in five of those medicated take two or more psychotropic medications at once. Medication has a legitimate role, but too often it substitutes for addressing the sleep, feeding, gastrointestinal, or communication problem driving the behavior in the first place.

The endpoint of that substitution is crisis care. Autism-related visits as a share of all pediatric emergency-department visits rose roughly 50% between 2016 and 2021, and a large share are driven by challenging behavior rather than medical emergency. Psychiatric emergency visits, boarding, and inpatient stays are among the costliest events in pediatric care — and many are preventable, the downstream product of comorbidities left unmanaged upstream. Poor sleep worsens aggression, self-injury, and inattention; untreated gastrointestinal pain intensifies distress; unaddressed communication deficits produce the very behaviors that trigger placement. Skipping whole-child care does not save money. It defers the cost, and it raises it.

Wiggins et al., J. Pediatrics / CDC (2021) · Rast et al., J. Autism Dev. Disord. (2023) · Trivedi et al., NHAMCS analysis (2024)

The Distinction

Comprehensive Is Not the Same as More.

There is a legitimate objection to any argument for additional services. The pediatric behavioral health sector has just lived through a decade of volume growth — applied behavior analysis visits alone rose 267% between 2019 and 2024 — that outpaced any reasonable estimate of clinical need and provoked the rate cuts, audits, and hour caps now reshaping the market. A call for “comprehensive care” that simply stacks more billable disciplines onto every child would repeat exactly that mistake, and payors would be right to reject it.

The distinction is dosing and fit. The most rigorous recent evidence finds that more hours do not produce better outcomes. A 2024 meta-analysis of 144 studies and more than 9,000 children found no significant dose-response relationship between the amount of intervention delivered and the outcomes achieved. The Department of Defense’s own evaluations of its TRICARE Autism Care Demonstration point the same way: the number of ABA hours delivered did not predict improvement on the program’s primary outcome measure, average symptom change was small and often sub-clinical, and what improvement did occur concentrated among the most severely affected children at baseline and the families with the highest treatment-plan adherence. Meanwhile, parent-mediated and group-based models achieve meaningful gains at a fraction of the cost of high-hour, one-to-one therapy.

The conclusion is not “more.” It is “right.” Whole-child care means treating the comorbidities that are actually present, at the intensity each child actually needs — and no more than that.

Sandbank et al., JAMA Pediatrics (2024) · U.S. Dept. of Defense, TRICARE Autism Care Demonstration Annual Report · Cheng et al., J. Autism Dev. Disord. (2023) · Trilliant Health (2025)

Care That Compounds

Four Pillars — and the Proof They Require.

A whole-child model has a recognizable shape, and four pillars define it. It is coordinated — beginning with early assessment across disciplines (speech and language, occupational and physical therapy, feeding, sleep, gastrointestinal health, and behavioral support) so the comorbidities driving a child’s presentation are identified rather than overshadowed. It is dosed — intensity matched to need, favoring parent-mediated and group delivery where the evidence supports it, and de-prescribing as readily as prescribing. It is caregiver-integrated — building the parent in as the between-session engine that makes gains generalize and hold, a mechanism parent-implemented intervention has shown to produce meaningful outcomes across dozens of studies; the operational framework for delivering this at scale is the Caregiver Optimization Model™, developed by Melissa Kozak, BCBA, an Archē Network member. And it is measured — outcomes-gated, so services that are not producing progress are changed or stopped, not renewed by default.

Each discipline already shows the logic at the unit level: behavioral sleep intervention is cost-effective and reduces medication use, intensive feeding therapy is a cost-effective alternative to long-term tube dependence, and earlier coordinated intervention is associated with better educational outcomes and less reliance on special education. But intellectual honesty requires naming the gap. The claim that comprehensive care lowers the total cost of care is well-supported in its mechanism and in its parts, yet it has not been proven at whole-population scale in a rigorous controlled trial. That is precisely why measurement is not optional. The value of whole-child care is realized only when it is delivered as an outcomes-driven system that can prove — child by child, discipline by discipline — that the right care, correctly dosed, improves function while avoiding the crises and lifetime costs that fragmentation makes near-certain. This is care that compounds: each coordinated intervention raising the value of the others, so that the whole is worth more than the sum of the visits.

Cheng et al., J. Autism Dev. Disord. (2023) · Kozak, M., Caregiver Optimization Model™ (2026) · Engel et al., Sleeping Sound CEA (2024) · Williams et al. (2007) · Dimian et al. (2021) · Economist Impact / Neurological Alliance (2024)

Why Archē

Better Care and a Better Business Are the Same Bet.

Archē Partners invests directly in the care delivery itself — not only the infrastructure around it — backing models that create greater value than any single visit can. The fragmentation of neurodevelopmental care is not only a clinical failure; it is one of the market’s largest unpriced inefficiencies, a system paying premium, downstream, crisis-driven prices for the predictable consequences of care it declined to coordinate upstream. The providers who organize care around the whole child — early, personalized, correctly dosed, caregiver-integrated, and measured — will convert that inefficiency into durable clinical and economic value.

We have spent a combined 15+ years working with founders and operators in multi-site healthcare services and medical technologies, executing transformational growth through inflection points. Across 85+ healthcare transactions as investors in equity and credit, we know what institutional buyers value: scaled leadership, clean financials, defensible economics, and a tangible growth story that outcomes data can substantiate. Whole-child care, delivered as an outcomes-driven system, produces exactly the evidence the next generation of payor contracts will require — and exactly the enterprise value the next generation of buyers will pay for. That alignment, between better care and a better business, is the thesis.